Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPHPC effect on HIV DNA vaccination
NCT02425241Phase 2Completed
- Sponsor
- University College London
- Start
- Oct 2013
- Primary completion
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of miridesap in human immunodeficiency virus type 1 infection (HIV-1), sponsored by University College London. Started Oct 2013; status: completed.
02
Drugs
miridesap
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT02425241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02425241.